-
Sino Biological and BioGeometry Broaden Partnership to Advance AI-Driven Drug Discovery
•
Sino Biological (SHE: 301047), a leading biotech company in China, and BioGeometry have announced an expansion of their partnership to harness generative artificial intelligence (AI) for drug discovery. While the financial details of the deal remain undisclosed, the collaboration aims to combine Sino Bio’s advanced protein expression and wet-lab expertise…
-
Sino Biological Inc. to Acquire Canadian Bioactive Enzyme Manufacturer SignalChem Biotech
•
Sino Biological Inc. (SHE: 301047), a leading provider of biological research reagents and technical contract research services based in China, has entered into a definitive Share Purchase Agreement to acquire SignalChem Biotech Inc. (SCB), a Vancouver, Canada-based manufacturer of specialized bioactive enzymes. The transaction values 100% of SCB’s shares at…
-
Sino Biological Partners with Rapid Novor to Market mAb Sequencing Services Across Asia
•
Sino Biological Inc. (SHE: 301047), a leading supplier of reagents based in China, has announced a partnership with Canada-based Rapid Novor Inc. Under the terms of the agreement, Sino Biological will market select services from Rapid Novor across multiple Asian markets, including China, Singapore, Thailand, Malaysia, Indonesia, Vietnam, the Philippines,…
-
VectorBuilder Partners with Sino Biological to Boost Global Biological Reagents Market
•
VectorBuilder, a genetic engineering specialist based in Guangzhou and nurtured by the state-owned Guangzhou Industrial Investment and Capital Operation Holding Group, has entered into a partnership with Sino Biological, Inc. (SHE: 301047), a global leader in the provision of mammalian cell-based recombinant proteins, antibodies, and related contract research services. This…
